Preparation, Characterization and In Vitro Drug Release Studies of 6-mercaptopurine Thin Film by Prem, K G et al.
63 
 
A Peer-reviewed Official International Journal of Wollega University, Ethiopia 
 DOI: http://dx.doi.org/10.4314/star.v3i2.8  
 ISSN: 2226-7522(Print) and 2305-3372 (Online)  
Science, Technology and Arts Research Journal  
Sci. Technol. Arts Res. J., April-June 2014, 3(2): 63-67 





Preparation, Characterization and In Vitro Drug Release Studies of                     
6-mercaptopurine Thin Film  
 
Prem Kumar G1*, Jagadeesh S. Sanganal1, Manohara C1, Swamy KB1, Aparna V1,       
Shridhar NB1, Narayana Swamy HD2, Ramachandra SG3 and Phani AR4 
 
1
Department of Veterinary Pharmacology and Toxicology, Veterinary College, Bangalore, Karnataka, India 
2
Department of Veterinary Pathology, Veterinary College, Bangalore, Karnataka, India 
3
Central Animal Facility, Indian Institute of Science, Bangalore, Karnataka, India 
4
Nano-RAM Technologies, Bangalore, Karnataka, India 
Abstract  Article Information 
Oral thin films of 6-mercaptopurine were fabricated from mucoadhesive polymer, 
chitosan and polyvinylpyrrolidone for the purpose of prolonging drug release and 
improving its bioavailability. All fabricated film formulations prepared were smooth 
and translucent, with good flexibility. The weight and thickness of all the 
formulations were found to be uniform. These films were also evaluated for surface 
pH, folding endurance, swelling percentage (% S) and in vitro disintegration time. 
Scanning Electron Microscopy (SEM) and Fourier Transform Infrared (FTIR) were 
used to evaluate the physico-chemical nature of the films. In-vitro drug release have 
shown enhanced release profiles for thin films compared to pure drug and the 
release patterns have been found to be pH dependant. The results of the study 
reveals that fabrication of 6-MP oral thin film by using solvent cast technology is a 
simple and an efficient method for drug delivery to achieve desired therapeutic 
compliance.     
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INTRODUCTION 
The thiopurines, azathioprine, 6-mercaptopurine and 
6-thioguanine are effective immune-suppressants and 
anti-cancer agents and are prescribed increasingly to treat 
inflammatory diseases (Estlin, 2001). 6-mercaptopurine  
(6-MP) was approved as an antitumor drug by Food and 
Drug Administration (FDA) in 1953 (Cuin et al., 2011) and 
has been widely used in the treatment of Acute 
Lymphoblastic Leukemia and Acute Myelocytic Leukemia 
(Sun et al., 2013; Karim et al., 2013) and other diseases 
such as rheumatologic disorders, prevention of rejection 
following organ transplantation, systemic lupus 
erythematosus, non-Hodgkin-lymphoma, inflammatory 
diseases (Crohn’s Syndrome and Ulcerative Colitis) and 
so on (Podsiadlo et al., 2008;  Kevadiya et al., 2013). 
 
6-MP is first metabolized to an active form methylated 
thioinosinic acid (MeTIMP) by hypoxanthine 
phosphoribosyltransferase (HPRT) within cell to inhibit de 
novo purine synthesis (Panetta et al., 2006) and later 
converted to thioguanine, which is a DNA intercalating 
agent. However, 6-MP undergoes extensive first pass 
catabolism by XO (Xanthine oxidase) and TPMT 
(thiopurine S methyl transferase) limiting their 
bioavailability. So this could lead to a lower bioavailability 
(about 16%) (Cheok and Evans, 2006), short plasma half-
life (0.5–1.5 h) (Zacchigna et al., 2007), with moderate 
plasma protein binding (19% to 30%) (Mawatari et al., 
2001) and plummeting chemotherapeutic effect. With a 
view to optimize the therapeutic effect of 6-MP, the 
objective of this investigation was to formulate 
mucoadhesive buccal films using chitosan-Polyvinyl 
pyrolidone (PVP) polymer complex for sustained release 
of the drug and to evaluate their physico-chemical 
characteristics by using SEM and FTIR.  
 
MATERIALS AND METHODS 
Materials 
6-mercaptopurine monohydrate (Assay purity ≥98.0%), 
Polyvinyl Pyrrolidine (PVP) (Mw= 13,00, 000), Chitosan 
low molecular weight (deacetylation ≥75.0 %), Acetic acid 
glacial (≥99.85%) and dialysis tubing cellulose membrane 
were purchased from Sigma-Aldrich Chemical Co. Ltd. 
Monobasic sodium phosphate (NaH2PO4) and Dibasic 
sodium phosphate (Na2HPO4) were purchased from 
Emplura
®
, Merck Specialities Pvt. Ltd., Bangalore, India. 
 
Preparation of Chitosan-PVP oral thin films 
Chitosan solution (2% w/v), was prepared by 
dissolving chitosan in 1% w/v acetic acid and then 6-
mercaptopurine (0.5 % w/v) was dispersed in the solution 
under constant magnetic stirring. PVP solution (2 % w/v), 
was prepared by dissolving PVP in ethanol by stirring it 
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continuously for about 10 mnt to obtain clear 
homogeneous solution. Chitosan-PVP blends solutions 
(1:2) were prepared by stirring for about half an hour. The 
obtained homogenous solutions were poured into a plastic 
mould, covered and kept overnight at room temperature 
for solvent evaporation. The resulting films were used for 
further physico-chemical analysis. 
 
Chitosan-PVP Oral Thin Film Characterization  
Scanning Electron Microscopy (SEM) 
The surface morphology of the oral thin films 
containing drug and polymer were characterized by Field 
Emission Scanning Electron Microscope (FESEM, FEI 
Sirion) at operating voltage of 5–30 KV. All images were 
recorded at working distance of 8-10 mm.  
 
FTIR Analysis 
The procedure involving sample preparation and 
spectral recordings was carried out by previously 
described method (Stuart et al., 2004). IR spectra of 6-
MP, PVP and oral films were recorded using FTIR Nicolet 
6700 (Thermo Fisher Scientific, Madisson, WI, USA) 
operated by Omnic software 8.1. In particular, for oral thin 
films measurement the spectra were obtained by 
attenuated total reflectance (ATR) method using smart 
orbit diamond ATR. Briefly, the formulations were placed 
individually on the sample plate of the smart orbit and 
screwed lightly to record IR spectra in ATR mode. 
 
Surface pH 
The surface pH of 6-mercaptopurine oral thin films was 
evaluated by using combined pH electrode. Films were 
moistened with milli-Q- water and pH was measured at 
the interphase of water and film (Prem et al., 2014). 
 
Thickness 
Thicknesses of these films were measured by 
calibrated digital Vernier callipers (Mitutoyo 550-203-10, 
Mitutoyo, Japan). Thickness was measured at four 
different points in the films and mean value was 
expressed (Raju et al., 2011). 
 
Folding Endurance 
Folding endurance was determined by repeatedly 
folding the film (4 Χ 4 cm) at the same point until a 
breaking point was achieved. Number of times the film 
could be folded at the same point without breaking was 
considered as folding endurance value. All the tests were 
performed four times and mean of the values was 
reported (Mona et al., 2012).  
 
Swelling Percentage (% S) 
Swelling index for the films was estimated in simulated 
salivary fluid at pH 6.8. Briefly, films (surface area 4 cm
2
) 
were weighed and transferred onto a petriplate containing 
buffer media (Wang et al., 2000). At definite time interval 
(15s), films were removed, blotted quickly with adsorbent 
paper, and then weighed. The percentage of water uptake 
was calculated as follows where Wf is the weight of wet 
grafted films and Wi is the weight of dry grafted films. 
 
(Wf – Wi) 
% S =   -------------- x 100 
Wi 
 
In Vitro Disintegration Time 
In vitro disintegration time was measured by following 
monograph from United States Pharmacopeia (USP) 
using disintegration test apparatus (LABINDIA, DS8000) 
(United States Pharmacopoeia, 2009). 
Drug Content  
A sample of 3 cm
2
 was dissolved in 10 ml methanol by 
vortex for 5 minute to extract drug from film and filtered 
through whatman filter paper and analyzed 
spectrophotometrically at 325 nm using methanol as a 
blank (Senthil et al., 2010). 
 
In Vitro Drug Release 
In vitro drug release studies were performed using 
USP Apparatus-I at 50 rpm and 600 ml of PBS (pH 3.4, 
6.4 and 7.4) at 37±0.5°C. A calculated 10 mg (conc. 
2mg/ml) of pure drug and Chitosan-PVP thin film were 
separately placed in dialysis tube and immersed in PBS at 
above mentioned pH. At predetermined time intervals (0, 
15, 30 min, 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, 16 h, 24 h and 48 
h, an aliquot of 4 ml of the release media was withdrawn 
and the concentration of the drug in release media was 
estimated by UV spectroscopy (Evolution 300; Thermo 
Fisher Scientific, USA) at 325nm. The dissolution medium 
was replaced with fresh buffer (4ml) to maintain constant 
total volume (Manohara et al., 2014). 
 
RESULTS AND DISCUSSION 
Physico-chemical Characterization 
SEM Analysis 
The prepared oral thin film of 6-MP is depicted in 
Figure 1. Scanning electron micrographs of the 6-MP thin 
film with low and high magnification images are depicted 
in the Figure 2a and 2b respectively. The diameter 
(500nm-2µm) of the distributed 6-MP microparticles in the 
film has been confirmed (Image software, provided by 
National Institutes of Health, USA).  
 
 




IR spectra of 6-MP and Chitosan-PVP showed the 
prominent peaks for functional group like N-H, C-H 
(aliphatic and aromatic), C-O and S-H. Fundamental 
vibrations of primary functional groups and its frequency 
(cm
-1
) of 6-MP, PVP-chitosan and 6-MP loaded PVP-
Chitosan thin films are depicted in Figure 3a, 3b, and 3c. 
Rresults suggests that on comparing the 6-mp films with 
PVP-Chitosan films,there is no interaction between the 6-
mp and PVP-Chitosan polymer complex which is 
confirmed by the preence of prominent peaks of functional 
groups and absence of any additional functional groups. 
(Figure 3 and Table 1). 
 




Figure 2: SEM images of PVP-Chitosan oral thin film of 6-mercaptopurine with low (a) and high (b) magnification 
 
 
Figure 3: IR spectra of a) 6-mercaptopurine, b) PVP-Chitosan and c) 6-Mercaptopurine loaded PVP-Chitosan thin film 
 
 
Table1: IR spectroscopic fundamental vibrations and frequencies (cm
-1
) of 6-MP, PVP-Chitosan and 6-MP thin film 
 



















N-H (stretch) 3424.27 N-H (stretch) 3352.38 N-H (stretch) 3419.28 
N-H (Bend) 1527.17 N-H (Bend) 1590.59 N-H (Bend) 1568.79 
C-H(stretch) 3095.11, 2994.48 C-H(stretch) 2871.53 C-H(stretch) 3095.13, 2994.04 
C-N 1343.98 C-N 1024.39 C-N 1343.91 
C=N 1609.31 O-H 3200 C-O 1011.73 
C=C 1669.70 C-O 1377.28 S-H 2672.36 











The surface pH of oral films has been determined in 
order to investigate the effect of pH on oral mucosa (Prem 
Kumar et al., 2014). The determined surface pH of the 6-
MP film was in range of 6.7±0.1, which was almost neutral 
and irritation free to the mucosal lining of the oral cavity. 
 
Thickness 
The films were evaluated for thickness using digital 
Vernier calipers and mean value was found to be 
0.436±0.003 mm which indicates the uniformity of the film 
(Raju et al., 2011). 
 
Folding Endurance 
Folding endurance helps in determining the 
mechanical strength of the films. Higher the folding 
endurance higher is the mechanical strength (Semalty et 
al., 2008). The folding endurance of the drug loaded films 
was 560 which signifies that these films are strong 
enough to handle.  
 
Swelling Percentage (S%)   
Penetration of solvent into the polymer matrix leads to 
increased weight of the films and facilitates diffusion of 
drug molecules from bulk of the matrix to external 
environment (Brazel and Peppas, 2000). The mean 
swelling percentage was found to be 30.63%.These 
results imply that the absorption of water by these films 
was considerable for the drug release. Indeed higher 
swelling properties can cause discomfort in oral cavity due 
to their bulk properties. 
In Vitro Disintegration Time 
Disintegration time gives an indication about onset of 
action which is desirable for oral thin films (Mishra and 
Amin, 2009). The calculated mean time for the film to 
disintegrate into complete fine particles was 0.36 minute 
and to completely disappear into the solution was 1.21 
minute. These values indicate that these films have 
optimum disintegration time.  
 
In Vitro Drug Release Studies  
In order to investigate 6-MP release behaviour of PVP-
Chitosan thin films, the thin films were incubated in 
different release media (phosphate buffer pH: 3.4, 6.4 and 
7.4) and assessed by double beam UV-visible 
spectrophotometer. Figure 4 demonstrates 6-MP release 
profiles up to 48h of incubation period. As shown in Figure 
4, PVP-Chitosan thin films showed an initial burst release 
of 6-MP in a period of 4-6 h for all incubation media (Aydin 
and Pulat, 2012). After this initial burst effect, a slower 
sustained and controlled release occurred throughout the 
incubation period. Cumulative drug release profiles of 6-
MP thin film at pH 3.4 (62%), 6.4 (72%) and 7.4 (82%); 
were better than release profiles of pure drug (46%, 48% 
and 45%) (Fig 4a, 4b and 4c). We could also observe 
significant fall in concentration of 6-MP pure drug (pH 3.4) 
from 16 hrs onwards, when compared to 6-MP thin film, 
whereas at pH 6.4 and 7.4 there was no sudden decline in 
concentration. Release profiles supported that 6-MP 
molecules were encapsulated among the positively 
charged hydrophilic chains. 
 
 
Figure 4: In vitro drug release of 6-MP from PVP-Chitosan thin film at pH a) 3.4 b) 6.4 c) 7.4 
 




In this study, we prepared 6-MP loaded PVP-Chitosan 
thin films for enhanced drug delivery. Results of the SEM 
images confirmed decreased size of the drug in the film. 
FTIR spectrum showed non-interaction of 6-MP and PVP-
Chitosan polymer matrix. In vitro drug release of 6-MP 
from the thin film has enhanced to a considerable extent. 
So these formulations can be an alternative for delivering 
6-MP, which could enhance solubility, bioavailability with 
its sustaining drug release process. The preparation of 
drug loaded PVP-chitosan films is a simple technique that 
can be easily scaled up. 
 
ACKNOWLEDGEMENTS 
All the authors are thankful to Department of 
Veterinary Pharmacology and Toxicology, Veterinary 
College, Bangalore and Nano Research for Advanced 
Materials and Technologies (NRT), Bangalore, for 




Aydin, R.S.T., Pulat, M. (2012). 5-Fluorouracil Encapsulated 
Chitosan Nanoparticles for pH-Stimulated Drug Delivery: 
Evaluation of Controlled Release Kinetics. Journal of 
Nanomaterial Article ID 313961. 
Brazel, C.S., Peppas, N.A. (2000). Modeling of drug release 
from swellable polymers, European Journal of 
Pharmaceutics and Biopharmaceutics 49: 47-58. 
Cheok, M.H., Evans, W.E. (2006). Acute lymphoblastic 
leukaemia: a model for the pharmacogenomics of cancer 
therapy. Nature Reviews Cancer 6: 117.   
Cuin, A., Massabni, A.C., Pereira, G.A., Leite, C.Q.F., Pavan, 
F.R., Costa, R.S., Heinrich, T.A., Costa-Neto, C.M. 
(2011). 6-mercaptopurine complexes with silver and gold 
ions: Anti-tuberculosis and anti-cancer activities. 
Biomedicine and Pharmacotherapy 65: 334-338.  
Estlin, E.J. (2001). Continuing therapy for childhood acute 
lymphoblastic leukaemia: clinical and cellular 
pharmacology of methotrexate, 6-mercaptopurine and 6-
thioguanine. Cancer Treatment Reviews 27: 351-363. 
Karim, H., Ghalali, A., Lafolie, P.S., Vitols, S., Fotoohi, A.K. 
(2013). Differential role of thiopurine methyltransferase in 
the cytotoxic effects of 6-mercaptopurine and 6-
thioguanine on human leukemia cells. Biochemical and 
Biophysical Research 437: 280-286. 
Kevadiya, B.D., Patel, T.A., Jhala, D.D., Thumbar, R.P., 
Brahmbhatt, H., Pandya, M.P., Rajkumar, S., Joshi, G.V., 
Gadhia, P.K., Tripathi, C.B. and Bajaj, H.C., 2012. 
Layered inorganic nanocomposites: a promising carrier 
for 5-fluorouracil (5-FU). European Journal of 
Pharmaceutics and Biopharmaceutics 81: 91. 
Manohara, C., Jagadeesh, S.S., Prem, K.G., Swamy, K.B., 
Phani A.R. (2014). Improved Dissolution rate of Piroxicam 
by fusion solid dispersion technique. Science, Technology 
and Arts Research Journal 3(1): 44-47. 
Mawatari, H., Unei, K., Nishimura, S., Sakura, N., Ueda, K. 
(2001). Comparative pharmacokinetics of oral 6-
mercaptopurine and intravenous 6-mercaptopurine 
riboside in children. Pediatrics International 43: 673-677. 
Mishra, R., Amin, A. (2009). Formulation development of 
taste masked rapidly dissolving films of cetirizine 
hydrochloride. Pharmaceutical Technology 33(2): 48-56. 
Mona, N., Mayank, N., Vikram, C. (2012). Formulation and 
evaluation of mouth dissolving film of antipsychotic drug 
aripiprazole. Der Pharmacia Lettre 4(4): 1221-1227. 
Panetta, J.C., Evans, W.E., Cheok, H. (2006). Mechanistic 
mathematical modelling of mercaptopurine effects on cell 
cycle of human acute lymphoblastic leukaemia cells. 
British Journal of Cancer 94: 93–100. 
Podsiadlo, P., Sinani, V.A., Bahng, J.H., Kam, N.W.S., Lee, 
J., Kotov, N.A. (2008). Gold Nanoparticles Enhance the 
Anti-Leukaemia Action of a 6-mercaptopurine 
Chemoherapeutic Agent. Langmuir 24: 568.  
Prem Kumar, G., Phani, A.R., Prasad, R.G.S.V., Sanganal, 
J.S., Manali, N., Gupta, R., Rashmi, N., Prabhakara, G.S., 
Paul Salins, C., Sandeep, K., Raju, D.B. (2014). 
Polyvinylpyrrolidone oral films of enrofloxacin: Film 
characterization and drug release. International Journal of 
Pharmaceutics 471: 146-152. 
Raju, S., Sandeep, R.P., Anirudh, K.V., Deepthi, A., 
Sreeramulu, R.K., Madhava, R.P.V. (2011). Flash release 
oral films of metoclopramide hydrochloride for pediatric 
use: Formulation and in-vitro evaluation. Journal of 
Chemical and Pharmaceutical Research 3(4): 636-646. 
Semalty, M., Semalty, A., Kumar, G. (2008). Formulation and 
Characterization of Mucoadhesive Buccal Films of 
Glipizide. Indian Journal of Pharmaceutical Sciences 
70(1): 43-48. 
Senthil, V., Suresh K,R., Nagaraju, C.V.V., Jawahar, N., 
Ganesh, G.N.K., Gowthamarajan, K. (2010). Design and 
development of hydrogen nanoparticles for 
mercaptopurine. Journal of Advanced Pharmaceutical 
Technology and Research 1(3): 334-337. 
Stuart, B. (2004). Infrared spectroscopy; Fundamentals and 
applications. John Wiley and Sons, Inc., USA. 
Sun, H., Wang, T., Liu, X., CHEN, P. (2013). A sensitive 
inhibition chemiluminescence method for the 
determination of 6-mercaptopurine in tablet and biological 
fluid using the reaction of luminol–Ag (III) complex in 
alkaline medium. Journal of Luminescence 134: 154-159. 
The United States Pharmacopoeia- National Fomulary-21, 
Asian Edn., U.S. Pharmacopoeial convention Inc 
Rockville MD. 2009, 726-727. 
Wang, D.M., Wu, T.T., Lin, F.C., Hou, J.Y., Lai, J.Y. (2000). A 
novel method for controlling the surface morphology of 
polymericmembranes. Journal of Membrane Science 
169(1): 39-51: 2000. 
Zacchigna, M., Cateni, F., Di-Luca, G., Drioli, S. (2007). A 
simple method for the preparation of PEG-6-
mercaptopurine for oral administration. Bioorganic and 
Medicinal Chemistry Letters 17: 6607–6609. 
  
 
